MILLENNIUM PHARMACEUTICALS, INC.
- Country
- ๐บ๐ธUnited States
- Ownership
- Subsidiary
- Established
- 1993-01-01
- Employees
- 1K
- Market Cap
- -
A Study of IXAZOMIB in Adult Patients With Lymphoma
- First Posted Date
- 2009-05-06
- Last Posted Date
- 2015-11-11
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 31
- Registration Number
- NCT00893464
- Locations
- ๐บ๐ธ
Tower Cancer Research Center, Beverly Hills, California, United States
๐บ๐ธUniversity of Wisconsin Madison, Madison, Wisconsin, United States
๐จ๐ฆJewish General Hospital, Montreal, Quebec, Canada
MLN8237 for Treatment of Participants With Ovarian, Fallopian Tube, or Peritoneal Carcinoma
- First Posted Date
- 2009-03-02
- Last Posted Date
- 2022-04-08
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 31
- Registration Number
- NCT00853307
- Locations
- ๐บ๐ธ
Summit Medical Group, Berkeley Heights, New Jersey, United States
Phase 2 Study of VELCADE With Fludarabine in Comparison to Rituximab With Fludarabine in Follicular Lymphoma Patients Previously Treated With Rituximab
- Conditions
- Interventions
- First Posted Date
- 2009-02-25
- Last Posted Date
- 2012-12-12
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT00850499
- Locations
- ๐ฌ๐ท
Laiko Hospital - 1st Dept. of Propaedeutic Internal Medicine, Athens, Greece
๐ฎ๐ฑSheba MC - Hematology Institute, Ramat Gan, Israel
๐ฎ๐ฑHadassah University Hospital - Hematology Department, Jerusalem, Israel
Phase I Study of TAK-701 in Adult Patients With Advanced Nonhematological Malignancies
- First Posted Date
- 2009-01-29
- Last Posted Date
- 2011-12-02
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 27
- Registration Number
- NCT00831896
- Locations
- ๐บ๐ธ
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
๐บ๐ธEmory University School of Medicine, Winship Cancer Institute, Atlanta, Georgia, United States
๐บ๐ธThe Sarah Cannon Research Institute, Nashville, Tennessee, United States
A Phase 2 Trial of MLN8237 in Adult Participants With Acute Myelogenous Leukemia and High-Grade Myelodysplastic Syndrome
- Conditions
- Interventions
- First Posted Date
- 2009-01-28
- Last Posted Date
- 2018-05-11
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 57
- Registration Number
- NCT00830518
- Locations
- ๐บ๐ธ
Hematology and Oncology Associates of Northern New Jersey, Morristown, New Jersey, United States
A Phase 1 Study of IXAZOMIB in Adult Patients With Advanced Nonhematologic Malignancies
- First Posted Date
- 2009-01-28
- Last Posted Date
- 2019-09-09
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 116
- Registration Number
- NCT00830869
- Locations
- ๐บ๐ธ
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
๐บ๐ธEmory University, Atlanta, Georgia, United States
๐บ๐ธUniversity of Washington- Seattle Cancer Care, Seattle, Washington, United States
A Phase 1 Dose Escalation Study of TAK-901 in Subjects With Advanced Hematologic Malignancies
- First Posted Date
- 2008-12-12
- Last Posted Date
- 2013-07-02
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 31
- Registration Number
- NCT00807677
- Locations
- ๐บ๐ธ
University of Michigan, Ann Arbor, Michigan, United States
Study of Alisertib (MLN8237) in Adults With Aggressive Non-Hodgkin's Lymphoma
- First Posted Date
- 2008-12-12
- Last Posted Date
- 2018-03-27
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT00807495
- Locations
- ๐บ๐ธ
Hematology Oncology Associates, Virtua Memorial Hospital Burlington County, Mount Holly, New Jersey, United States
Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis
- First Posted Date
- 2008-11-02
- Last Posted Date
- 2014-07-18
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 895
- Registration Number
- NCT00783718
- Locations
- ๐บ๐ธ
Gastroenterology Associates of Central Georgia, Macon, Georgia, United States
๐บ๐ธCedars-Sinai Medical Center, Los Angeles, California, United States
๐บ๐ธBoston Medical Center, Boston, Massachusetts, United States
Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease
- First Posted Date
- 2008-11-02
- Last Posted Date
- 2014-07-21
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 1116
- Registration Number
- NCT00783692
- Locations
- ๐บ๐ธ
Puget Sound Medical Research, Edmonds, Washington, United States
๐บ๐ธRush University Medical Center, Chicago, Illinois, United States
๐บ๐ธUniversity of Pittsburgh Medical Center - Cancer Centers, Pittsburgh, Pennsylvania, United States